Drug Shortage Threat From Second COVID-19 Wave
Problems Are Expected But API Supplies May Not Be At Great Risk
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
You may also be interested in...
A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.
As part of its expanded mandate, the EU regulator is identifying those medicines whose supply will need to be closely monitored during health crisis situations. The lists will draw on various information sources, including real-world evidence databases.